Catalog No. Size PriceQuantity
M7832-2 2mg solid $100
M7832-10 10mg solid $300


Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.

Product information

CAS Number: 212141-54-3

Molecular Weight: 346.81

Formula: C20H15ClN4



PTK 787


ZK 222584



CGP 79787




PTK787/ZK 222584


Related CAS Number:

212142-18-2 (Vatalanib succinate)

212141-51-0 (Vatalanib hydrochloride)

Chemical Name: N-(4-chlorophenyl)-4-[(pyridin-4-yl)methyl]phthalazin-1-amine

Smiles: ClC1C=CC(=CC=1)NC1=NN=C(CC2C=CN=CC=2)C2=CC=CC=C21


InChi: InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 85 mg/mLwarmed(202.51 mM). Water: 10 mg/mL(23.82 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Vatalanib also inhibits Flk, c-Kit and PDGFRβ with IC50 of 270 nM, 730 nM and 580 nM, respectively. Furthermore, Vatalanib shows the anti-proliferation effect by inhibiting thymidine incorporation induced by VEGF in HUVECs with and IC50 of 7.1 nM, and dose-dependently suppresses VEGF-induced survival and migration of endothelial cells in the same dose range without cytotoxic or antiproliferative effect on cells that do not express VEGF receptors. A recent study shows that Vatalanib significantly inhibits the growth of hepatocellular carcinoma cells and enhances the IFN/5-FU induced apoptosis by increasing proteins levels of Bax and reduced Bcl-xL and Bcl-2.

In Vivo:

Vatalanib induces dose-dependent inhibition of the angiogenic response to VEGF and PDGF in both a growth factor implant model and a tumor cell-driven angiogenesis model after once-daily oral dosing (25-100 mg/kg). In the same dose range, Vatalanib also inhibits the growth and metastasesof several human carcinomas in nude mice without significant effect on circulating blood cells or bone marrow leukocytes.


  1. Murakami M, et al. Ann Surg Oncol. 2011, 18(2), 589-596.
  2. Wood JM, et al. Cancer Res. 2000, 60(8), 2178-2189.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed